Related Experiment Video
Updated: Feb 8, 2026

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
Published on: June 25, 2019
Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition
Luka Suzuki1, Takeshi Miyatsuka1, Miwa Himuro1
1Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Abstract:
Everolimus, an orally administered mammalian target of rapamycin inhibitor, has been widely used as an immunosuppressant and an anticancer agent. Whereas everolimus can control recurrent hypoglycemia in patients with insulinoma, possibly through tumor regression and/or the direct inhibition of insulin secretion, time-dependent changes in serum insulin levels caused by everolimus still remain unclear. Here we report a clinical case of a patient with metastatic insulinoma, in which frequent monitoring of serum insulin levels demonstrated rapid and substantial changes in insulin secretion levels, a few days after the discontinuation as well as the readministration of everolimus. To further confirm the direct effect of everolimus on β-cell function, we performed in vitro experiments using mouse insulinoma cells (MIN6) and human induced pluripotent stem cell (hiPSC)-derived insulin-producing cells and found that everolimus significantly suppressed glucose-stimulated insulin secretion in both MIN6 cells and hiPSC-derived insulin-producing cells. Thus, both a patient with metastatic insulinoma and in vitro experiments demonstrated that everolimus directly suppresses insulin secretion, independently of its tumor regression effect.
Insights
Everolimus, a mTOR inhibitor, directly suppresses insulin secretion in insulinoma patients and cells. This finding clarifies its role in managing hypoglycemia beyond tumor regression.
Area of Science:
- Endocrinology
- Pharmacology
- Oncology
Background:
- Everolimus (mTOR inhibitor) is used for immunosuppression and cancer.
- It manages hypoglycemia in insulinoma, but its effect on insulin secretion timing is unclear.
- Potential mechanisms include tumor regression and direct insulin secretion inhibition.
Purpose of the Study:
- To investigate the time-dependent effects of everolimus on serum insulin levels in metastatic insulinoma.
- To confirm the direct impact of everolimus on pancreatic beta-cell function.
- To elucidate the mechanism of everolimus in controlling hypoglycemia.
Main Methods:
- Clinical case study with frequent monitoring of serum insulin levels.
- In vitro experiments using mouse insulinoma (MIN6) cells.
- In vitro experiments using human induced pluripotent stem cell (hiPSC)-derived insulin-producing cells.
Main Results:
- Observed rapid, substantial changes in serum insulin levels following everolimus discontinuation and re-administration in a patient.
- Demonstrated significant suppression of glucose-stimulated insulin secretion in MIN6 cells.
- Confirmed suppression of glucose-stimulated insulin secretion in hiPSC-derived insulin-producing cells.
Conclusions:
- Everolimus directly suppresses insulin secretion from pancreatic beta-cells.
- This direct effect is independent of tumor regression.
- Provides a clearer understanding of everolimus's mechanism in managing insulinoma-related hypoglycemia.
More Related Videos
Related Concept Videos
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Cells and Secretions of the Pancreas
Exocrine function is carried out by acinar cells, organized into clusters known as acini. These cells contribute to digestion by releasing substantial quantities of enzyme-rich, alkaline digestive juices.
Concurrently, the dispersed clusters of endocrine cells throughout the...
Introduction to Test of Independence
The test statistic for a test of independence is similar to that of a goodness-of-fit test:
Hypothesis Test for Test of Independence
H0: The two variables (factors)...
Feedback Inhibition
Law of Independent Assortment

